Skip to main content

Topic

Drug Labeling

96 published works

  1. Drug & Device Law

    New Jersey Accutane Plaintiff Verdict Vacated – Appellate Division Strongly Criticizes Evidentiary Rulings

    By Michelle Yeary

    If you read the decision in Rossitto v. Hoffmann-LaRoche Inc., 2016 N.J. Super. Unpub. LEXIS 1714 (N.J. App. Div. Jul 22, 2016), we think you’ll agree with our calling it…

  2. Drug & Device Law

    Stick a Fork in It – FDA Anti-Generic Drug Preemption Proposal Postponed Until After the Presidential Election

    By Bexis

    On May 18, the FDA extended the comment period for its proposed generic drug labeling rule until April 2017 – that is, until after the next presidential election.  We believe…

  3. Drug & Device Law

    Breaking News – FDA Generic Drug Anti-Preemption Proposal Again Deferred

    By Bexis

    We just read on 360 this morning that the FDA has again postponed its schedule for finalizing the generic drug labeling changes (the so-called "Supplemental Applications Proposing Labeling Changes for…

  4. Drug & Device Law

    Incretin Preemption Part II – California Tosses Failure to Warn Claims Too

    By Michelle Yeary

    This post is from the non-Reed Smith side of the blog. Last week we posted about the decision in In re Incretin-Based Therapies Products Liability Litigation (S.D. Cal.) dismissing plaintiffs’ failure to warn…

  5. Food Safety News

    DOJ Seeks Criminal Contempt Sanctions Against MT Supplements Seller

    By News Desk

    On one of his websites, Toby McAdam, 57, is letting prospective customers know that he cannot sell his dietary supplements until he works out a labeling issue with the U.S.…

  6. The Brand Protection Blog

    Canadian plain language labelling requirements take effect for drug products

    By Karen Sie (CA)

    The Regulations Amending the Food and Drug Regulations (Labelling, Packaging and Brand Names of Drugs for Human Use) - more commonly known as the “Plain Language Labelling amendments” - as…

  7. Product Liability & Mass Torts Blog

    FDA Reopens Comment Period for Drug Labeling Rule

    By Matthew J. Fischer, Jamie Lynn Lanphear

    The consequences of the Supreme Court’s decision in Pliva v. Mensing continue to play out on multiple tracks.  Most recently, the FDA has reopened the comment period for its proposed…

  8. Drug & Device Law

    Breaking News – First Circuit Extends Mensing Preemption To Innovator Drugs

    By Bexis

    We’ve argued since PLIVA v. Mensing, 131 S. Ct. 2567 (2011), was first decided that its impossibility preemption rationale extended to innovator/branded drugs and was not limited to generics. We’ve…

  9. Health Care and Life Sciences

    The Rise of the Online Package Insert?

    By Benjamin M. Zegarelli

    On December 18, 2014, FDA released proposed regulations that would make prescribing information for drugs and biologics available online and prohibit distribution of paper copies as part of product packaging. …

  10. Life Sciences Legal Update

    FDA Announces Plan to Encourage Voluntary Updating of Drug and Biologics Labels

    By Lisa Baird

    As mentioned on our Health Industry Washington Watch blog, the U.S. Food and Drug Administration (FDA) has announced a plan intended to incentivize manufacturers to voluntarily update their prescription drug…